GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Language
Years
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Editora Cubo ; 2013
    In:  Autopsy and Case Reports Vol. 3, No. 2 ( 2013)
    In: Autopsy and Case Reports, Editora Cubo, Vol. 3, No. 2 ( 2013)
    Type of Medium: Online Resource
    ISSN: 2236-1960
    Language: English
    Publisher: Editora Cubo
    Publication Date: 2013
    detail.hit.zdb_id: 2815488-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 3014-3014
    Abstract: Background: Germline genetic factors central to immunity, such as human leukocyte antigen (HLA) variants, have been associated with several immune-related phenotypes such as response to immune checkpoint inhibitors. However, HLA and killer-cell immunoglobulin-like (KIR) gene combinations, which may modulate immune function, have not been studied in relation to T-cell density in cancer. Methods: This study was conducted within 3 well characterized epidemiologic studies that collected colorectal tumor tissue blocks (N=484). We profiled the in-situ T cell landscape of CRC using digital imaging, machine learning, and a customized 9-plex multiplexed immunofluorescence panel with antibodies directed against CD3, CD4, CD8, CD45RA, CD45RO, FOXP3, and MKI67. HLA and KIR variants were imputed from genome-wide array datasets through SNP2HLA and KIR*IMP methods. We used multivariable ordinal logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between HLA-KIR activation/inhibition ligand combinations with quartile of T cell densities in CRC adjusting for age, sex, GWAS panel, and the first two principal components of ancestry. Results: Presence of KIR2DL2+HLAC1+ and KIR2DS2+HLAC1+ combinations were associated with lower odds of greater CD3+CD8+ T-cell density quartile, however these findings were not statistically significant [OR = 0.73, 95% CI (0.52, 1.02), p-value = 0.067; OR = 0.74 95% CI (0.53, 1.04), p-value= 0.082, respectively]. There was no association between HLA-KIR combinations and CD3+CD4+ T-cell density quartile. Further results will examine HLA and KIR genes individually, as well as additional combination variables and more specific T-cell density subsets. Conclusions: Further investigation is needed to determine if germline genetics related to immune profile plays a role in T-cell densities in CRC. Citation Format: Claire Elizabeth Thomas, Jeroen Huyghe, Tomotaka Ugai, Hang Yin, Yasutoshi Takashima, Daniel D. Buchanan, Conghui Qu, Li Hsu, Andressa Dias Costa, Stephen Gallinger, Robert Grant, Sushma Thomas, Shuji Ogino, Amanda I. Phipps, Jonathan Nowak, Ulrike Peters. Association between HLA-KIR allele interaction combinations and density of T-cell subsets in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3014.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 684-684
    Abstract: Abstract Background: Biological evidence indicates that obesity influences immune responses, interacting with various immune cell populations via obesity-related systemic inflammation. We hypothesized that the association of obesity with colorectal cancer (CRC) incidence differed by T-cell, macrophage, and other myeloid cell infiltrates in tumor tissue. Methods: We developed multiplexed immunofluorescence assays to identify immune cells, including T-cell (CD3, CD4, CD8, CD45RO, and FOXP3), macrophage [CD68, CD86, IRF5, MAF, and MRC1 (CD206)], and myeloid cell (CD14, CD15, HLA-DR, ARG) subsets in tumor. Utilizing the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS), we examined the association of body mass index (BMI) with incidence of CRC subtypes classified by each immune cell subset. We applied inverse probability-weighted Cox proportional hazards models to control for selection bias and potential confounders. We used the stringent α level of 0.005 due to multiple comparisons. Results: During follow-up of 131,144 participants (3,648,371 person-years), we documented 3,203 incident CRC cases including 886 CRC cases with available data on immune cell densities in tumor tissue. The association of cumulative average BMI (from baseline to the most recent questionnaire cycle) with CRC incidence differed by CD15+CD33- cell (mature granulocyte) densities in tumor intraepithelial regions (Phet=0.004). Cumulative average BMI was associated with incidence of tumors with low CD15+CD33- cell densities [18.5-22.5 kg/m2: reference; 22.5-24.9 kg/m2: HR (95% CI), 1.67 (1.12-2.48); 25.0-27.5 kg/m2: 1.73 (1.14-2.61); 27.5-29.9 kg/m2: 2.06 (1.32-3.21); ≥30 kg/m2: HR, 2.26 (1.45-3.52), Ptrend & lt;0.001], but not with incidence of tumors with intermediate or high CD15+CD33- cell densities (Ptrend & gt;0.049, with the α level of 0.005). The association of young adult BMI (at age 18 for NHS and at age 21 for HPFS) with CRC incidence differed by CD15+CD33+ cell [granulocytic myeloid-derived suppressor cell (MDSC)-like phenotype] densities in tumor intraepithelial regions (Phet & lt;0.001). Young adult BMI was associated with incidence of tumors with low CD15+CD33+ cell densities [18.5-22.5 kg/m2: reference; 22.5-24.9 kg/m2: HR (95% CI), 1.18 (0.96-1.44); 25.0-27.5 kg/m2: 1.44 (1.11-1.87); ≥27.5 kg/m2: 1.88 (1.35-2.62), Ptrend & lt;0.001], but the association was attenuated for tumors with intermediate and high CD15+CD33+ cell densities (Ptrend & gt;0.087). Similar differential associations were not observed in analyses of CRC subclassified by T cell or macrophage densities. Conclusions: The association of BMI with CRC incidence differed by intraepithelial myeloid cell densities. Our findings suggest an interplay of obesity from early life and granulocytic MDSCs/other granulocytes in colorectal carcinogenesis. Citation Format: Tomotaka Ugai, Juha P. Väyrynen, Yasutoshi Takashima, Seyed Mostafa Mousavi Kahaki, Benjamin Langworthy, Koichiro Haruki, Naohiko Akimoto, Mai Chan Lau, Rong Zhong, Sara A. Väyrynen, Melissa Zhao, Andressa Dias Costa, Jennifer Borowsky, Jennifer L. Guerriero, Xuehong Zhang, Andrew T. Chan, Molin Wang, Marios Giannakis, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Jonathan A. Nowak, Shuji Ogino. Body mass index throughout adulthood and incidence of colorectal cancer subclassified by T cell, macrophage, and myeloid cell infiltrates in cancer tissue [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 684.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 22_Supplement ( 2022-11-15), p. PR005-PR005
    Abstract: In preclinical work, the inflammatory cytokine IL-1β was shown to be upregulated in pancreatic cancer tumors and to contribute to activation of pancreatic stellate cells and immunosuppression (Das et al 2020). We conducted an open-label multicenter Phase Ib study evaluating gemcitabine, nab-paclitaxel, canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) mAb, and spartalizumab (PDR001), a PD-1 mAb. Eligible subjects had previously untreated metastatic PDA and RECIST measurable disease. The primary objective was to confirm recommended phase II dose by evaluating the incidence of dose limiting toxicities (DLTs) in the first 56 days of dosing in at least 6 evaluable subjects utilizing a Bayesian logistic regression model. Subjects underwent baseline and on-study tissue and blood collection for correlative translational research. Results: 10 subjects were enrolled between Nov 2020 and Mar 2021. At the primary data cut off of May 23, 2021, 6 subjects were evaluable for DLT. There were no DLTs, the recommended Phase II dose was established as: gemcitabine (1000mg/m2 IV) day 1,8,15; nab-paclitaxel (125mg/m2 IV) day 1,8,15; canakinumab (250mg SC) day 1, spartalizumab (400mg IV) day 1; of each 28 day cycle. At the time of an updated database extraction on June 1, 2022, 2 subjects remain on study. Adverse events were consistent with those typically seen with chemotherapy. The most common Grade 3/4 AEs were neutropenia (60%) and anemia (50%), with no fatal AEs. One patient discontinued spartalizumab due to grade 3 pneumonitis. In preliminary efficacy analysis (n=10), there are 3 confirmed PRs, 5 subjects with stable disease, 2 subjects with progression as best response. Individual site data estimates that the 12 month OS rate is 60%; updated RR, PFS and OS data will be reported. Activation of CD8 T cells in peripheral blood and increased serum levels of IFN-induced chemokines CXCL9/10 were observed in both responder and non-responder patients. Using an in vitro suppression assay, we showed that baseline serum from responders could induce myeloid derived suppressor cells, an effect that was abrogated with treatment. Single cell transcriptional profiling, multiplex immunofluorescence and spatial transcriptomics also revealed treatment-dependent shifts in T cell activation state and myeloid cells in the tumors of patients experiencing clinical response. Conclusions: PanCAN-SR1 established the Phase II dose of canakinumab and spartalizumab with chemotherapy in first line metastatic PDA, based upon favorable benefit-risk assessment. Based on our comprehensive analysis of 10 patients treated with combination therapy including IL-1b blockade, we hypothesize that the definitive role of anti-IL-1b in human patients with pancreatic cancer is to reduce systemic immune suppression and to reduce immunosuppressive myeloid cell activation in the tumor. The clinical utility of targeting IL-1β in pancreatic cancer is being evaluated in a randomized Phase II/III study through the Precision Promise clinical trial network. NCT04581343. Citation Format: Paul E. Oberstein, Osama Rahma, Nina Beri, Amy Stoll-D'Astice, Emily A. Kawaler, Igor Dolgalev, Gregor Werba, Victoire Cardo-Ruffino, Naïma Böllenrücher, Andressa Dias Costa, Saloney Nazeer, Matthew Squires, Jonathan Nowak, Dafna Bar-Sagi, Brian Wolpin, Diane M Simeone, Stephanie K Dougan. Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr PR005.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2733-2733
    Abstract: Background: Biological evidence indicates that smoking influences immune responses through interacting with various immune cell populations. We therefore hypothesized that the association of smoking with colorectal cancer (CRC) incidence differs by T-cell, tumor-associated macrophage (TAM), and myeloid cell densities. Methods: We developed multiplexed immunofluorescence assays to identify immune cells, including T-cell subsets (CD3, CD4, CD8, CD45RO, and FOXP3), TAMs (overall, M1-like, M2-like), and myeloid cell subsets (CD14, CD15, HLA-DR, ARG) in tumor intraepithelial and stromal areas. Utilizing the Nurses' Health Study and the Health Professionals Follow-up Study, we examined the association of smoking with incidence of CRC subtypes classified by each immune cell subset. We applied inverse probability weighted Cox proportional hazards regression models to control for selection bias and potential confounders. Results: During follow-up of 131,144 participants (3,648,371 person-years), we documented 3,203 incident CRC cases including 871 CRC cases with available data on immune cell densities in tumor tissue. The association of pack-years smoked with colorectal cancer incidence was stronger for tumors with lower CD3+CD8+ T-cell densities (Pheterogeneity=0.074) and lower overall TAM densities (Pheterogeneity=0.004) in tumor stromal areas. Further, the association of pack-years smoked with colorectal cancer incidence was stronger for tumors with higher CD14+HLA-DR− immature monocytic myeloid cell densities (Pheterogeneity=0.001) in tumor intraepithelial areas. Conclusions: The association of smoking with CRC incidence differed by stromal CD3+CD8+ T-cell densities, stromal TAM densities, and intraepithelial CD14+HLA-DR− myeloid cell densities. Our findings suggest a complex interplay of T-cells, TAMs, and myeloid cells in smoking-related colorectal carcinogenesis. Cumulative Pack-years Smoked and Colorectal Cancer Incidence, Overall and by Immune Cell DensityCumulative Pack-years Smoked01-1920-39≥40P for trendP for heterogeneityAll colorectal cancer (N=871)361209149152--Multivariable HR (95% CI)1 (referent)1.06 (0.93-1.22)1.08 (0.92-1.25)1.25 (1.07-1.46)0.007-Stromal CD3+CD8+ cell density------Low (N=310)124685761--Multivariable HR (95% CI)1 (referent)1.07 (0.79-1.45)1.25 (0.91-1.73)1.46 (1.07-2.00)0.0120.074Intermediate (N=280)111764449--Multivariable HR (95% CI)1 (referent)1.24 (0.92-1.66)1.04 (0.73-1.47)1.38 (0.98-1.94)0.15-High (N=281)126664643--Multivariable HR (95% CI)1 (referent)0.91 (0.68-1.23)0.89 (0.64-1.26)0.98 (0.70-1.39)0.85-Stromal Macrophage density------Low (N=288)106715061--Multivariable HR (95% CI)1 (referent)1.31 (0.97-1.78)1.30 (0.92-1.84)1.70 (1.23-2.35)0.0030.004Intermediate (N=294)125605356--Multivariable HR (95% CI)1 (referent)0.82 (0.60-1.13)1.03 (0.75-1.43)1.36 (0.99-1.86)0.045-High (N=289)130784635--Multivariable HR (95% CI)1 (referent)1.12 (0.84-1.48)0.95 (0.67-1.33)0.80 (0.55-1.17)0.20-Intraepithelial CD14+HLA-DR− cell density-----Low (N=290)130763945--Multivariable HR (95% CI)1 (referent)1.08 (0.82-1.44)0.77 (0.54-1.11)0.99 (0.70-1.40)0.510.001Intermediate (N=285)120724350--Multivariable HR (95% CI)1 (referent)1.04 (0.77-1.40)0.89 (0.63-1.27)1.26 (0.90-1.77)0.36-High (N=279)98596656--Multivariable HR (95% CI)1 (referent)1.18 (0.85-1.62)1.85 (1.34-2.55)1.75 (1.26-2.44) & lt;0.001- Citation Format: Tomotaka Ugai, Juha P. Väyrynen, Koichiro Haruki, Naohiko Akimoto, Mai Chan Lau, Rong Zhong, Sara A. Väyrynen, Melissa Zhao, Andressa Dias Costa, Jennifer Borowsky, Jennifer L. Guerriero, Charles S. Fuchs, Xuehong Zhang, Molin Wang, Marios Giannakis, Jeffrey A. Meyerhardt, Jonathan A. Nowak, Shuji Ogino. Smoking and colorectal cancer Iincidence by tumor microenvironment in cancer tissue [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2733.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Editora Cubo ; 2014
    In:  Autopsy and Case Reports Vol. 4, No. 2 ( 2014), p. 27-33
    In: Autopsy and Case Reports, Editora Cubo, Vol. 4, No. 2 ( 2014), p. 27-33
    Type of Medium: Online Resource
    ISSN: 2236-1960
    Language: English
    Publisher: Editora Cubo
    Publication Date: 2014
    detail.hit.zdb_id: 2815488-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 7_Supplement ( 2023-04-04), p. 5760-5760
    Abstract: Background: Despite heightened interest in early-onset CRC, little is known about the tumor molecular, immune, and microbial characteristics of early-onset CRC. It is also unclear whether CRCs diagnosed at or shortly after age 50 are similar to early-onset CRC. We hypothesized that tumor molecular, immune, and microbial characteristics in CRC tissue might show differential heterogeneity patterns between three age groups ( & lt;50 "early-onset", 50-54 "intermediate-onset", ≥55 "later-onset"). Methods: We examined 3,395 CRC cases with available tissue data, including 660 early-onset and 243 intermediate-onset cases in the Nurses' Health Study, Health Professionals Follow-up Study, and Ontario Familial Colon Cancer Registry. We profiled the in situ T-cell landscape of 959 cases using digital imaging, machine learning, and a customized 9-plex multiplexed immunofluoresence panel with antibodies directed against CD3, CD4, CD8, CD45RA, CD45RO, FOXP3, and MKI67 (Ki-67). Using chi-squared test or Spearman’s correlation test, we assessed differences in tumor characteristics including microsatellite instability, CpG island methylator phenotype (CIMP), KRAS, and BRAF mutations, LINE-1 methylation levels, pks+ E. coli and Fusobacterium nucleatum positivity, histopathologic lymphocytic reaction, and T-cell densities between early-onset, intermediate-onset, and later-onset cases. Results: Compared to later-onset CRC (21%), early-onset (4.8%) and intermediate-onset CRCs (5.1%) exhibited a lower prevalence of CIMP-high status (P & lt;0.001). The mean tumor LINE-1 methylation level increased with increasing age [59 (SD, 12) in early-onset, 61 (SD, 10) in intermediate-onset, and 64 (SD, 9.8) in later-onset CRC (P & lt;0.001)]. Early-onset CRC (4.1%) had fewer BRAF mutations than intermediate-onset (10.4%) and later-onset CRC (15%) (P & lt;0.001). Compared to later-onset CRC, early-onset CRC tended to show lower levels of tumor-infiltrating lymphocytes (P=0.013), and intratumoral periglandular reaction (P=0.025). Compared to later-onset CRC, early-onset CRC had a lower density of memory (both CD4+ and CD8+) T-cells (median 21 vs. 48 cells/mm2; P=0.002) and a higher density of MKI67+ immune cells (median 50 vs. 19 cells/mm2; P=0.003) in tumor epithelial areas but not in the surrounding stroma. No significant differences in other tested characteristics were identified. Conclusions: Compared to later-onset CRC, early-onset and intermediate-onset CRCs tended to have aggressive tumor phenotypes such as LINE-1 hypomethylation, lower lymphocytic immune reaction, and a higher density of MKI67+ immune cells. These findings highlight the importance of the tumor microenvironment in the etiology of early-onset and intermediate-onset CRCs. Citation Format: Tomotaka Ugai, Yasutoshi Takashima, Andressa Dias Costa, Daniel Buchanan, Jeroen Huyghe, Li Hsu, Conghui Qu, Claire Thomas, Steve Gallinger, Robert Grant, Ulrike Peters, Amanda I. Phipps, Jonathan Nowak, Shuji Ogino. Molecular, immune, and microbial profiles of early-onset, intermediate-onset, and later-onset CRCs. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5760.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 22_Supplement ( 2020-11-15), p. PR-001-PR-001
    Abstract: Background: Neoadjuvant therapy (neoTX) may improve survival for patients with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC). However, the impact of neoTX on the tumor immune microenvironment is incompletely understood, hampering efforts to identify optimal treatment combinations and predictive markers to guide patient selection. Design: We employed digital image analysis and three multiplex immunofluorescence (mIF) assays, comprising 15 immune cell markers, to identify T cell subpopulations, macrophage polarization and myeloid cell subpopulations in primary resected PDAC. A multi-institution cohort of untreated tumors (n=299) was analyzed to characterize the baseline tumor immune microenvironment, while resected tumors after FOLFIRINOX-based neoTX (n=36) or upfront surgery (n=30) were analyzed to identify immune microenvironmental change due to neoTX. Multivariable Cox proportional hazard regression models were used to assess associations with patient outcomes. Results: Macrophages, T lymphocytes, and granulocytes were all abundant in the previously-untreated PDAC microenvironment, yet their densities exhibited substantial heterogeneity across patient tumors. In the untreated multi-institutional cohort, higher CD3+ T cell density was associated with longer disease-free survival (DFS) and overall survival (OS), while M2-polarized macrophages and CD15+ARG1+ immunosuppressive granulocytes were associated with shorter survival times. In particular, a higher ratio of CD3+CD8+ T cells to CD15+ARG1+ immunosuppressive granulocytes was associated with longer DFS (Q4 vs. Q1 HR 0.46, Ptrend=0.002) and OS (Q4 vs. Q1 HR 0.70, Ptrend=0.02). While neoTX did not alter overall CD3+ density, it increased the relative proportion of CD3+CD8+ cells, resulting in a lower CD4/CD8 ratio (p & lt;0.001), and an elevated CD3+CD8+ to CD15+ARG1+ ratio (p & lt;0.001). Similarly, neoTX did not alter overall macrophage density, but it shifted the relative polarization balance towards an M1 phenotype (p & lt;0.001) and increased the number of M1 macrophages spatially co-localized with tumor cells (p & lt;0.001). Higher degree of M1 macrophage:tumor cell colocalization was associated with better histologic response (p & lt;0.001) and longer OS (High vs. Low HR 0.15, Ptrend=0.01). Finally, although neoTX did not alter either overall CD14+ or CD15+ myeloid cell density, it reduced CD15+ARG1+ immunosuppressive granulocyte density (p=0.01). Inclusion of radiotherapy (long-course chemoradiation, n=4 or SBRT, n=8) as part of neoadjuvant treatment was associated with few additional alterations in the immune microenvironment. Conclusion: While neoadjuvant chemotherapy minimally affects overall immune cell density, it significantly shifts the PDAC immune microenvironment towards an anti-tumorigenic state characterized by more CD8+ T cells and M1-polarized macrophages and fewer immunosuppressive granulocytes. These data may inform future neoadjuvant treatment strategies. Citation Format: Andressa Dias Costa, Sara Väyrynen, Akhil Chawla, Jinming Zhang, Juha P. Väyrynen, Mai Chan Lau, Hannah L. Williams, Chen Yuan, Vicente Morales-Oyarvide, Douglas A. Rubinson, Thomas E. Clancy, Lauren K. Brais, Emma Reilly, Margaret M. Kozak, David C. Linehan, Richard F. Dunne, Daniel T. Chang, Aram F. Hezel, Albert C. Koong, Andrew J. Aguirre, Brian M. Wolpin, Jonathan A. Nowak. Neoadjuvant therapy is associated with altered composition of immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr PR-001.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Cell, Elsevier BV, Vol. 184, No. 25 ( 2021-12), p. 6119-6137.e26
    Type of Medium: Online Resource
    ISSN: 0092-8674
    RVK:
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 187009-9
    detail.hit.zdb_id: 2001951-8
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 22_Supplement ( 2022-11-15), p. B018-B018
    Abstract: Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the US with a 11% 5-year survival rate. A key contributor of this dismal prognosis is early and frequent metastatic spread with limited treatment options for patients. Metastasis in PDA is facilitated by a robust fibroinflammatory response in the primary tumor site, a large portion of which is composed of infiltrating immune cells, and survival during transit to establish in the secondary site. In the primary tumor reactive stroma, we found increased eosinophils in both human and mouse PDA compared to the normal pancreas. Eosinophils are an innate immune cell best known for their ability to control parasite responses and have been implicated in either pro- or anti-cancer roles in various solid tumors. We used the ΔdblGata mice, which lack eosinophils, to study the role of eosinophils during metastatic spread using a resectable model of PDA metastasis. This model of metastasis was developed to facilitate consistent seeding of lung metastasis in approximately 50 percent of mice from a transient subcutaneous tumor which undergoes subsequent surgical removal and harvest to evaluate metastasis at 4 weeks. We found that mice lacking eosinophils have increased metastasis to the lung in our resectable model of PDA metastasis but no difference in establishment of IV injected PDA tumor cells, suggesting eosinophil control at the primary tumor site. Single cell sequencing of the subcutaneous tumors finds differences in the angiogenic subtypes, tip and stalk cells, in mice lacking eosinophils. Sequencing of eosinophil populations in humans and mice find an increase in angiogenic signaling suggesting a regulatory role in tumor cell access to the circulation. We conclude that eosinophils in PDA inhibit the metastatic process through control of angiogenic signaling. Citation Format: Megan T. Hoffman, Patrick J. Lenehan, Jennifer Wang, Lestat Ali, Li Qiang, Amiko Uchida, Sara Vayrynen, Andressa Dias Costa, Michael Dougan, Max Heckler, Jonathan Nowak, Brian W. Wolpin, Stephanie K. Dougan. Eosinophils alter metastatic spread in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr B018.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...